Establishing a Longitudinal Cohort Study of Lung Cancer Using Tissue and Peripheral Blood Metabolomics.

Launched by THE FIRST AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIVERSITY · Feb 24, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the role of metabolomics, which looks at the chemical processes in the body, to better understand lung cancer. Researchers will collect tissue and blood samples from patients at important stages of their treatment to find out how these metabolic changes can help in diagnosing lung cancer, predicting treatment success, and monitoring long-term outcomes. The study aims to identify markers that could help tell the difference between benign (non-cancerous) and malignant (cancerous) lung nodules and improve personalized care for lung cancer patients.

To participate in this trial, individuals should be between 18 and 75 years old and have lung nodules confirmed by a CT scan. They also need to have good lung function and be able to cooperate with the testing process. Participants will undergo various evaluations, including imaging and pulmonary function tests, at key points, such as before surgery and during treatment. The goal is to gather valuable information that could lead to better management of lung cancer in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Signing of the informed consent form;
• • 2. Male or female, aged 18-75 years;
• • 3. Patients with lung nodules confirmed by CT examination;
• • 4. Good preoperative pulmonary function cooperation and complete reporting;
• • 5. Preoperative chest single/dual phase CT scans without significant artefacts and with complete imaging;
• • 6. The interval between preoperative pulmonary function and single/dual phase CT scans does not exceed one month.
• Exclusion Criteria:
• • 1. Poor preoperative pulmonary function cooperation or missing reports;
• • 2. Preoperative chest single/dual phase CT scans exhibit significant artefacts or image omission;
• • 3. The interval between preoperative pulmonary function and single/dual phase CT scans exceeds one month;
• • 4. Complication with severe respiratory disorders (such as lung transplantation, pneumothorax, giant bullae, etc.);
• • 5. Coexisting with other severe functional impairments;
• • 6. Patients with obstructive lesions such as airway or esophageal stenosis;
• • (8) Medication use before pulmonary function testing that does not meet the cessation guidelines; (9) Pulmonary function report quality graded D-F.